Impact of PEP Buddy on Breathing, Exercise, and Sleep in COPD Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of the PEP Buddy device in improving breathing, exercise tolerance, and sleep quality among patients with chronic obstructive pulmonary disease (COPD). It focuses on patients aged 55-65 with moderate to severe COPD, utilizing positive expiratory pressure (PEP) during aerobic exercise to enhance self-management and reduce dyspnea. The study aims to demonstrate that PEP can lead to significant improvements in quality of life by addressing common symptoms associated with COPD. Participants will engage in a structured exercise program while using the PEP Buddy device to maximize benefits.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* • All gender COPD patients

  * Age will be 55-65 years.
  * Moderate to severe COPD patients
  * emphysema on CT scan (HU ≥ - 900)
  * Their FEV1 will be less than 80% predicted
  * Class II obesity (BMI of 35 to \< 40)
  * Medically stable
  * greater than 10 pack-year smoking history

Exclusion Criteria:

* • Very severe COPD - Lung cancer

  * Lung resection - Lung fibrosis
  * Heart failure - Cognitive disorders that affect the device application
  * Musculoskeletal or neurological disorders that interfere with an exercise program
  * requiring invasive or non-invasive positive pressure ventilation
  * inability to speak in complete sentences due to breathlessness
  * suspected elevated intracranial pressure - hemodynamic instability
  * recent facial, oral, or skull surgery
  * active hemoptysis (more than two tablespoons of frank blood per day)
  * pneumothorax - failure to comply with the research protocol.
  * uncontrolled hypertension, or other concomitant respiratory diseases
  * participate in any research or pulmonary rehabilitation program during the period of this study.
  * imaging changes of lung disease such as occupancy, exudation, and interstitial changes on CT scan

Where it's running

• Faculty of Physical Therapy
  Giza, Dokki, Egypt Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ensa?fentrine to help prevent COPD flare-ups in adults on standard care

  This study tests whether ensifentrine (MK-5884) can help prevent moderate or severe COPD exacerbations compared with placebo in adults already receiving standard COPD treatment.

  Recruiting at 7 sites Phase 3 Merck Sharp & Dohme LLC · Hialeah Gardens, Florida and 6 other locations · NCT07874815

• GSK Investigational Medicine GSK3862995B: two formulations in healthy adults

  This early-phase study tests two formulations of GSK3862995B in healthy adults to see how the body handles the drug and whether it is safe and tolerable.

  Recruiting Phase 1 GlaxoSmithKline · Cambridge · NCT07789899

• GSK5784283 added to standard COPD therapy vs placebo in moderate to very severe COPD

  This study tests whether adding GSK5784283 to current COPD treatment reduces the rate of COPD flare-ups in adults with eosinophilic COPD and a history of exacerbations.

  Recruiting at 7 sites Phase 3 GlaxoSmithKline · Doral, Florida and 6 other locations · NCT07780669

• GSK5784283 added to standard COPD care versus placebo in adults with moderate to very severe COPD

  This study tests whether adding GSK5784283 to a patient’s current COPD treatment helps reduce COPD flare-ups compared with a placebo in adults with eosinophilic COPD and a history of frequent exacerbations.

  Recruiting at 8 sites Phase 3 GlaxoSmithKline · Cape Coral, Florida and 7 other locations · NCT07780656

• Brenipatide for adults with moderate-to-severe COPD

  This study tests different doses of Brenipatide to see if it is safe and effective for adults with moderate-to-severe COPD, compared with placebo.

  Recruiting at 69 sites Phase 2 Eli Lilly and Company · Birmingham, Alabama and 126 other locations · NCT07759245

• Early depemokimab treatment for COPD with type 2 (eosinophilic) inflammation

  This trial will test whether adding depemokimab early to standard care helps adults with moderate-to-severe COPD who have type 2 (eosinophilic) inflammation.

  Recruiting at 121 sites Phase 3 GlaxoSmithKline · Newport Beach, California and 120 other locations · NCT07177339

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.